Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00077779 · ClinicalTrials.gov registry record · Phase 3
Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
A Phase 3 study of Crohn's Disease, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 854
- Enrollment target
- 20
- Study locations
NCT00077779: Completed Phase 3 study of Crohn's Disease, sponsored by Abbott.
NCT00077779 is a Phase 3 study of Crohn's Disease that has completed, run by Abbott. The registered enrollment target is 854 participants, below the 2,386-participant average among 105 other Crohn's Disease trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00077779, a Phase 3 study of Crohn's Disease, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 854 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)
Conditions Studied
Interventions
- DRUG Adalimumab
Study Locations (20)
Florida
- Clinical Research of West Florida, Inc. - Clearwater
- V.A. Medical Center - Gainsville
- Mark Lamet, MD - Hollywood
- Gastroenterology Consultants - Ormond Beach
California
- Thornton Hospital Reumatology Division - La Jolla
- UCSF San Francisco General Hospital - San Francisco
- Cal-West, Inc. - San Francisco
Illinois
- Northwest Gastroenterology - Arlington Heights
- Northwestern University - Chicago
- The University of Chicago - Chicago
Maryland
- Maryland Clinical Trials - Annapolis
- Chevy Chase Clinical Research - Chevy Chase
- Capital Gastroenterology Consultants, P.A. - Silver Spring
Indiana
- Indianapolis Gastroenterology Research Foundation - Indianapolis
- St. Vincent Hospital: Research Department - Indianapolis
Colorado
- Western States Clinical Research - Arvada
Connecticut
- Gastroenterology Associates of Fairfield County - Bridgeport
Louisiana
- Drug Research Services, Inc. - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 854 participants |
| Start Date | 2003-07 |
| Phase | Phase 3 |
What the finished NCT00077779 record still lists
NCT00077779 is an interventional study that assigns participants to a tested intervention. The registered 854 participants enrollment target is mid-sized for trials with a published cap, below the 2,386-participant average among 105 other Crohn's Disease trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Crohn's Disease appearing as the primary indexed condition, and to 1 intervention - of which Adalimumab is the first listed.
NCT00077779 names 20 study sites across 10 states, led by Florida, California, Illinois.
Frequently Asked Questions
What is clinical trial NCT00077779 about?
NCT00077779 is a clinical study titled "Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease". The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)
What is the current status of trial NCT00077779?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 854 participants. The study started on 2003-07.
What conditions does trial NCT00077779 study?
This clinical trial studies the following conditions: Crohn's Disease.
What interventions are being tested in trial NCT00077779?
The interventions under investigation include: Adalimumab (DRUG).
Who is sponsoring clinical trial NCT00077779?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00077779 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00077779's enrollment target sits among peer trials
854 13th of 105 higher than 93 of 105 other Crohn's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease
RECRUITING · Phase 3
-
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
RECRUITING · Phase 3
-
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
RECRUITING · Phase 3
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
-
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
RECRUITING · Phase 3
-
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07005102 · 854 participants · Phase 2
A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
- NCT07290491 · 854 participants · Phase 3
Spiritual Care or Psychotherapy Versus Palliative Care Alone in Patients With Non-Curative Malignancies
- NCT05108896 · 855 participants · NA
Aspiration in Acute Respiratory Failure Survivors 2
- NCT06231485 · 856 participants · NA
Socialization To Enrich Participation & Support Sexuality for Young People With I/DD
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia